Deucravacitinib for Psoriatic Arthritis

Recruiting in Palo Alto (17 mi)

+475 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Bristol-Myers Squibb

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a new medication called deucravacitinib to see if it can help people with psoriatic arthritis who haven't tried advanced treatments. The medication works by reducing joint swelling and pain by blocking inflammation. Deucravacitinib is a new oral drug that has shown good results in previous studies for psoriasis.

Eligibility Criteria

This trial is for individuals with active psoriatic arthritis who haven't used biologic disease-modifying anti-rheumatic drugs. They should have at least 3 swollen and tender joints, a diagnosis of PsA for 3+ months, an active skin lesion or history of plaque psoriasis, and certain levels of inflammation markers in their blood.

Inclusion Criteria

I have finished a year-long treatment in a previous study phase.

I have been diagnosed with psoriatic arthritis for at least 3 months.

My X-rays show at least one erosion in my hand or foot joints due to PsA.

Exclusion Criteria

I have an autoimmune condition like lupus or multiple sclerosis.

I have or had joint inflammation not caused by PsA, like gout or rheumatoid arthritis.

I do not have plaque psoriasis currently.

Participant Groups

The study tests the effectiveness and safety of Deucravacitinib compared to a placebo in treating psoriatic arthritis. Participants will be randomly assigned to receive either the drug or placebo to assess long-term effects.

Group I: Deucravacitinib Experimental Treatment 1 Intervention

Group II: Placebo Placebo Group 1 Intervention

Deucravacitinib is already approved in United States, European Union, Canada for the following indications:

🇺🇸 Approved in United States as Sotyktu for:

• Moderate to severe plaque psoriasis

🇪🇺 Approved in European Union as Sotyktu for:

• Moderate to severe plaque psoriasis

🇨🇦 Approved in Canada as Sotyktu for:

• Moderate to severe plaque psoriasis

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Local Institution - 0087 Boise, ID

Local Institution Gainesville, GA

Clinic of Robert Hozman, MD/Clinical Investigation Specialists, Inc. Skokie, IL

Local Institution Allen, TX

More Trial Locations

Who Is Running the Clinical Trial?

Bristol-Myers Squibb Lead Sponsor

References